Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?

Novo Nordisk shares have fallen more than 60% over two years as GLP-1 market-share losses and clinical setbacks weigh on its outlook; the stock trades at 11.8x forward earnings versus an 18.6x healthcare-stock average. Q2 sales rose 2% year over year to DKK 78.5 billion and adjusted EPS increased 5% to DKK 6.18. Oral Wegovy had more than 3 million U.S. prescriptions filled by June, while zenagamtide showed up to 24.3% mean weight loss over 36 weeks in an early-stage study; future returns depend on successful pipeline development.

Analysis

The key valuation question is whether Novo’s forward earnings are a durable base or a denominator about to reset. A low multiple versus healthcare is not a margin of safety if volume, net pricing, or estimates are still adjusting to competition. For the oral launch, prescription counts matter less than net revenue, refill persistence, payer coverage, and whether uptake is incremental rather than a shift from Novo’s own injectables. Broader access could grow the category, but it may also intensify price competition and raise the value of manufacturing scale and commercial execution.

Over the next 1–3 months, sales mix, realized pricing, and management guidance are more actionable than early-stage pipeline promise. Over 6–18 months, phase 3 data for zenagamtide and other candidates could improve Novo’s strategic value, but clinical efficacy must translate into tolerability, adherence, and a commercially differentiated product; phase 1/2 results alone do not establish that. Lilly is positioned to benefit if Novo’s share losses persist, though a stronger-than-expected oral launch or differentiated Novo data could reverse relative performance.

Contrarian point: the market may be discounting pipeline uncertainty correctly, while underestimating the risk that earnings estimates lag deteriorating product economics. Conversely, treating all GLP-1 growth as zero-sum could understate category expansion from oral access. The article provides no net-price, refill, supply, or valuation-estimate detail, so an outright NVO value call is premature.

Key Decisions for Investors

• Prefer a modest relative-value position—long Eli Lilly and underweight Novo—rather than a large outright short in Novo. Enter gradually; the thesis is relative execution and earnings durability, not certainty that the GLP-1 market is fixed-size.
• Add to the relative position only if upcoming results show continued Novo share or guidance pressure and oral prescriptions fail to convert into durable net sales. Reduce or close it if Novo demonstrates sustained refill growth, favorable net pricing, and stable guidance.
• Treat zenagamtide and other pipeline programs as catalyst optionality, not near-term earnings support. Reassess on phase 3 efficacy, safety, and discontinuation data; a clearly differentiated result would challenge the underweight thesis.
• Track oral product net revenue, payer access, refill persistence, supply availability, and injectable cannibalization. Prescription totals without these measures are insufficient to validate incremental growth.
• No standalone NVO long is compelling on the supplied evidence alone: the discount may be justified if forward earnings are at risk. A sustained improvement in sales growth and earnings guidance would falsify that cautious view.